Study Review: A Single Dose of Lion’s Mane Did Not Improve Overall Cognition
Lion’s Mane is sold almost entirely on a cognitive promise, and the marketing language around it tends to move faster than the evidence underneath it. So when a placebo-controlled trial tests that promise directly, it is worth reading closely, including the parts that do not flatter the ingredient.
This one is worth reading twice, because it is frequently cited as support for Lion’s Mane and focus, and its primary result was null.
The study
Surendran G, Saye J, Jalil SBM, et al. Acute effects of a standardised extract of Hericium erinaceus (Lion’s Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study. Frontiers in Nutrition. 2025;12:1405796. doi:10.3389/fnut.2025.1405796
What they did
Eighteen healthy adults, ten male and eight female, mean age about 23, took part in a double-blind, randomised, placebo-controlled crossover. Each person completed both conditions, active and control, with a seven-day washout between test days. Crossover is the right design here, because each participant serves as their own comparison and you need far fewer people to see an effect.
The active dose was 3 grams of a 10:1 Hericium erinaceus fruiting body extract, produced by water and ethanol extraction and made up of 95 percent extract with 5 percent maltodextrin. The authors describe this as roughly equivalent to 30 grams of fresh fruiting body. It was mixed into a 250 mL drink with lemon squash. Two points there are worth noting for label readers: this was fruiting body rather than mycelium on grain, and the dose was a single acute serving, not a daily course.
Testing happened at baseline and again 90 minutes after the drink. The primary outcome was a composite global cognition score built from six tasks: Trail Making Test A and B, Digit Span, Digit Symbol Substitution, Grooved Pegboard, the Deary-Liewald reaction time task, and a Flanker task. Mood was a secondary outcome, measured with the PANAS scale.
What they found
The primary outcome did not move. There were no significant main effects or interactions on the global cognitive composite, and none on the mood composite either. Positive affect, negative affect, and overall mood were all unchanged. In the authors’ own framing, acute consumption did not demonstrate significant overall improvement.
Underneath that null headline, the individual tasks were mixed in both directions.
- Grooved Pegboard, a manual dexterity and fine motor speed task, improved. Dominant hand performance was better after the active drink than at baseline (p less than 0.001) and better than after the control drink (p equals 0.01). Non-dominant hand also improved from baseline after the active drink (p less than 0.001), while it declined from baseline after the control drink (p equals 0.03).
- Flanker task performance was worse after the active drink than after the control drink (p less than 0.001).
- Trail Making Test B declined from baseline after the active drink (p equals 0.01).
So the one clear positive signal was on a fine motor speed task, and two attention and executive function measures moved the wrong way. When a composite is null and the individual tasks scatter in both directions, the honest reading is that this is noise-level variation across many comparisons, not a demonstrated cognitive benefit.
Who paid for it
Beyond Alcohol Ltd, trading as Three Spirit Drinks, contributed to the publication fees. Two of the authors are employed by that company, which uses Hericium erinaceus in its products. The remaining authors reported no conflicts.
This does not make the study wrong. Industry funding is common across supplement research, and it is arguably more informative here than usual: a company-associated trial that reported a null primary outcome and two results pointing the wrong way is not a paper written to sell anything. That is a point in favour of the reporting, not against it.
What it does not tell you
The authors are direct about the limits, and we agree with most of them.
Eighteen people is a small sample even for a crossover, and the study was underpowered for the composite it was built around. The design was acute, one dose, one measurement window, which is not the question most buyers are actually asking. Testing at 90 minutes may have landed before peak concentration, and the pharmacokinetics of these compounds in humans are not well characterised, so the timing was a reasonable guess rather than a targeted one. Healthy young adults have little room to improve on standard cognitive tasks, which compresses any effect that might exist. And extract composition varies enormously between products, so a result for this specific 10:1 fruiting body extract does not transfer cleanly to whatever is in another bottle.
Our read
This is evidence about one acute dose in healthy young people, and on that narrow question the answer was no measurable overall benefit. It is not evidence that Lion’s Mane does nothing over weeks of daily use, which is a different study that this one did not run.
What it does do is set a standard for reading citations. If a brand points to human trial evidence for cognitive claims, check whether the primary outcome was met or whether the citation rests on one favourable sub-measure inside a null result. That distinction separates most of the strong marketing in this category from the actual literature.
We score products on what their own testing documents, not on which papers their marketing links to. Studies like this are why.